/

Empresas

J

No verificado

J INTS BIO

Sobre qué escribimos

BiologíaEconomíaFarmacéuticaSanidadStart-up

7 Comunicados de prensa

Ver todos los comunicados de prensa

02/06/2025

Farmacéutica

Sanidad

Biología

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Fuente

Editor

1.00

0

30/04/2025

Farmacéutica

Sanidad

Finanzas

Ciencia

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025

Fuente

Editor

1.00

0

Press Release cover image

25/11/2024

Farmacéutica

Sanidad

Economía

Start-up

Finanzas

Biología

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy

Fuente

Editor

1.00

0

Press Release cover image

05/11/2024

Farmacéutica

Sanidad

Economía

Start-up

Biología

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Fuente

Editor

1.00

0

Press Release cover image

24/10/2024

Farmacéutica

Sanidad

Biología

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

Fuente

Editor

1.00

0

Press Release cover image

24/10/2024

Farmacéutica

Sanidad

Finanzas

Biología

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

Fuente

Editor

1.00

0

Press Release cover image

10/06/2024

Farmacéutica

Sanidad

Biología

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0